When results from the three groups of patients with cancer were individually compared with the controls and patients with BPH, IL-6 levels were significantly higher in patients with metastatic disease (mean 9.3±7.8 pg ml−1, median 7.0 pg ml−1, P<0.001). This evidence concerns the gene IL6 and benign prostatic hyperplasia.